CoChat

Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Restenosis, the principal complication of percutaneous transluminal coronary angioplasty is responsible for the 35-40% long-term failure rate following coronary revascularization. The neointimal formation, a morphological substrate of restenosis, is dependent on smooth muscle cells (SMC) proliferation and migration. Signal transduction through the platelet-derived growth factor (PDGF)/PDGF receptors system is involved in the process of post-angioplasty restenosis. The unsuccessful attempts to control restenosis by systemic pharmacological interventions have prompted many researchers to look for more promising therapeutic approaches such as local drug delivery. Tyrphostins are low molecular weight inhibitors of protein tyrosine kinases. We assessed the release kinetics and in vivo effects of nanoparticles containing PDGF-Receptor beta (PDGFRbeta) tyrphostin inhibitor, AG-1295. AG-1295-loaded poly(DL-lactide) (PLA) nanoparticles were prepared by spontaneous emulsification/solvent displacement technique. In vitro release rate and the impact of drug/polymer ratio on the nanoparticle size were determined. The degree of tyrosine phosphorylation was assessed by Western blot with phosphotyrosine-specific antibody in rat SMC extracts. Several bands characteristic of PDGF BB-stimulated SMC disappeared or weakened following tyrphostin treatment. Local intraluminal delivery of AG-1295-loaded PLA nanoparticles to the injured rat carotid artery had no effect on proliferative activity in medial and neointimal compartments of angioplastisized arteries, indicating a primary antimigration effect of AG-1295 on medial SMC.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0168-3659(99)00244-8

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 40 references

Cited by

See all 89

Metadata

Authors
Fishbein, I., Chorny, M., Rabinovich, L., Banai, S., Gati, I., & Golomb, G.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • Bikur Cholim Hospital (IL)
Corresponding author
Golomb, Gershon
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2000-03
Volume
65
Issue
1-2
Pages
221-229
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2084651791
Cited by
89
References
40
Citations by year
2025: 1 · 2024: 2 · 2023: 4 · 2022: 1 · 2021: 6 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 6 · 2015: 2 · 2014: 5 · 2013: 1 · 2012: 1
FWCI
5.31
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
Funders
Hebrew University of Jerusalem
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords
restenosis, tyrphostin, PDGF receptor beta, protein tyrosine kinase inhibitors, local drug delivery, smooth muscle cell proliferation, smooth muscle cell migration, neointima formation, percutaneous transluminal coronary angioplasty, drug release kinetics, tyrosine phosphorylation, carotid artery injury
MeSH terms
Animals, Aorta, Abdominal, Carotid Arteries, Cell Division, Cells, Cultured, Graft Occlusion, Vascular, Male, Microscopy, Fluorescence, Microspheres, Particle Size, Platelet-Derived Growth Factor, Tissue Distribution, Drug Delivery Systems, Tyrphostins, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. https://app.cochat.ai/papers/10.1016/s0168-3659(99)00244-8
The paper
Fishbein, I., Chorny, M., Rabinovich, L., Banai, S., Gati, I., & Golomb, G. (2000). Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. Journal of Controlled Release. https://doi.org/10.1016/s0168-3659(99)00244-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.